Impact of Different Modes of Ventilation With Laryngeal Mask Airway on Pediatric Cataract Surgery

NCT04241653 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-06-10

No results posted yet for this study

Summary

This study will be conducted to evaluate effects of different modes of ventilation on pediatric cataract surgery aiming to a peri-operative stable anesthesia, better surgical satisfaction and post operative recovery. It is hypothesized that controlled ventilation without muscle relaxation will be advantageous to other modes in providing adequate surgical satisfaction with considerable depth of anesthesia and better recovery profile.

Conditions

  • Ventilation
  • Laryngeal Mask Airway
  • Cataract Surgery

Interventions

PROCEDURE

Pressure Support Ventilation

Ventilator will be adjusted to administer pressure at 10 cmH2O.

PROCEDURE

Unparalyzed Pressure Control Ventilation

Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.

PROCEDURE

Paralyzed Pressure Control Ventilation

Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.

DEVICE

Laryngeal Mask Airway

Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.

DRUG

Sevoflurane

Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.

Sponsors & Collaborators

  • Sameh Fathy

    lead OTHER

Principal Investigators

  • Sameh M El-Sherbiny, MD · Mansoura Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2021-01-10
Completion
2021-02-09

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04241653 on ClinicalTrials.gov